Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07607158

Influence of the Gut Microbiome on Blueberry Polyphenol Metabolites

The objective of this study is to determine whether inter-individual differences in the gut microbiome influence exposure to blueberry polyphenol metabolites. We will use pharmacokinetics of blueberry polyphenols after an acute blueberry exposure to group individuals into "metabotypes", groups of individuals based on similarity in their metabolite profiles. We will then use multi-omic approaches to determine whether the gut microbiome predicts an individual's metabotype.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Colorado State University; Food and Nutrition Clinical Research Laboratory; Gifford Building Room 216; 502 West Lake Street, Fort Collins, CO 80523

Fort Collins, Colorado, 80523, United States

Location status: Recruiting

Location contact

Jenny Whittington, MS

CONTACT

[email protected]

970-310-6843

Tiffany Weir, PhD

CONTACT

[email protected]

Tiffany Weir, PhD

PRINCIPAL_INVESTIGATOR

About this study

This study is an acute, single-arm polyphenol pharmacokinetic study designed to evaluate inter-individual variability in the metabolism of blueberry polyphenols and the role of the gut microbiome in shaping these responses. The study will be conducted at Colorado State University in the Food & Nutrition Clinical Research Laboratory. We will enroll approximately 125 healthy adults (≥18 years of age), with stratified recruitment across a range of ages and body mass index (BMI) values to capture diversity in gut microbiome composition. Participants will provide written informed consent prior to participation and will be compensated for their time.

Eligible participants will be generally healthy adults able to provide informed consent and adhere to study procedures. Key exclusion criteria include pregnancy or breastfeeding; pre-specified chronic diseases; recent antibiotic use; conditions affecting nutrient absorption; anemia; BMI ≤18.5 kg/m²; unwillingness to adhere to study protocols; recent blood draw within 1 week; participation in another research study; and contraindications to study procedures, treatments, or supplies.

The study consists of three main components: a screening visit, an acute test day, and a 24-hour follow-up visit. During the initial screening visit, participants will complete a health and medical history questionnaire, anthropometric assessments, blood pressure measurements, and a fasting blood draw to assess metabolic health and eligibility.

Following screening, participants will complete a short lead-in period prior to the test day, during which they will collect stool samples and a 24-hour urine sample at home and complete three 24-hour dietary recalls. They will also follow a low-polyphenol diet for three days prior to the test visit to minimize background variability in polyphenol exposure.

On the test day, participants will report to the laboratory following an overnight fast. Participants will consume a standardized blueberry beverage containing freeze-dried blueberry powder. Serial blood samples will be collected via an indwelling catheter at baseline and at multiple time points over an 8-hour period (0, 1, 2, 4, 6, and 8 hours) to characterize the pharmacokinetics of circulating blueberry polyphenol metabolites. Additional blood samples will be collected for peripheral blood mononuclear cell (PBMC) isolation at hours 4 and 6. Standardized low-polyphenol meals and snacks will be provided during the visit. Participants will also initiate a 24-hour urine collection and receive a stool collection kit for post-visit sampling.

Participants will return approximately 24 hours after blueberry consumption for a follow-up visit, which includes an additional fasting blood draw and return of urine and stool samples.

Throughout the study, additional data will be collected via validated questionnaires assessing gastrointestinal symptoms, sleep quality, physical activity, diet, and social determinants of health. Biological samples (blood, urine, and stool) will be used to assess polyphenol metabolism, gut microbiome composition and function, and related multi-omic profiles.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adults ≥18 years of age
  • Able and willing to provide informed consent
  • Willing and able to adhere to all study procedures and visit requirements

Exclusion criteria

  • Age <18 years
  • Pregnant or breastfeeding
  • Presence of chronic diseases, including but not limited to cardiovascular disease, diabetes, cancer, kidney, liver, gastrointestinal, or pancreatic disease
  • Use of medications for chronic diseases that may interfere with study outcomes
  • Any condition known to negatively impact nutrient absorption (e.g., inflammatory bowel disease, celiac disease, gastroparesis)
  • Anemia (hemoglobin <13.5 g/dL in men or <12.0 g/dL in women)
  • Body mass index (BMI) ≤18.5 kg/m²
  • Use of antibiotics within the past 2 months
  • Recent blood draw within 1 week prior to study participation
  • Currently participating in another research study involving a diet or exercise intervention
  • Known allergy or contraindication to blueberry products or study procedures
  • Unwilling or unable to comply with study requirements

Treatment and study plan

Freeze-dried blueberry powder beverage

Other

Participants will consume a single oral dose of a standardized blueberry beverage prepared with 22 g of freeze-dried blueberry powder reconstituted in approximately 480 mL of distilled water. The beverage will be consumed in its entirety at the start of the test visit following an overnight fast. This dose is selected to provide a defined quantity of blueberry-derived polyphenols for pharmacokinetic assessment. No additional interventions or comparator treatments will be administered.

Primary outcomes

  1. Pharmacokinetics - Area under the curve (AUC) of circulating blueberry polyphenol metabolites

    Time frame: Baseline and 1, 2, 4, 6, 8 and 24 hours post-consumption

    Pharmacokinetics - Area under the curve (AUC) will be calculated from plasma concentrations of blueberry-derived polyphenol metabolites, measured at serial time points following a single-dose blueberry intervention.

  2. Pharmacokinetics - Maximum concentration (Cmax) of circulating blueberry polyphenol metabolites

    Time frame: Baseline and 1, 2, 4, 6, 8 and 24 hours post-consumption

    Pharmacokinetics - Maximum concentration (Cmax) will be calculated from plasma concentrations of blueberry-derived polyphenol metabolites, measured at serial time points following a single-dose blueberry intervention.

  3. Pharmacokinetics - Time to maximum concentration (Tmax) of circulating blueberry polyphenol metabolites

    Time frame: Baseline and 1, 2, 4, 6, 8 and 24 hours post-consumption

    Pharmacokinetics - Time to maximum concentration (Tmax) will be calculated from plasma concentrations of blueberry-derived polyphenol metabolites, measured at serial time points following a single-dose blueberry intervention.

Secondary outcomes

  1. Urinary excretion of blueberry polyphenol metabolites

    Time frame: up to 24 hours post-consumption

    Urinary concentrations of blueberry-derived polyphenol metabolites will be measured via 24-hour urine collection to assess excretion profiles following a single-dose blueberry intervention.

  2. Gut microbial taxonomic profiling

    Time frame: Baseline

    16s rRNA gene amplicon sequencing of stool samples will be used for exploratory gut microbial taxonomic profiling.

  3. Gut microbial functional potential

    Time frame: Baseline

    Metagenomic shotgun sequencing of stool samples will be used for exploratory profiling of gut microbial functional potential.

  4. Gut microbial transcripts

    Time frame: Baseline

    Metatranscriptomics will be used for exploratory profiling of gut microbial transcripts.

  5. Polyphenol Metabotype

    Time frame: Baseline

    Machine learning methods will be used to determine participant polyphenol metabotypes from pharmacokinetic profiles.

Study contacts

Contact information is provided by the study sponsor or research team.

Jenny Whittington, MS

CONTACT

[email protected]

(970) 310-6843

Tiffany Weir, PhD

CONTACT

[email protected]

(970) 491-4631

Sponsors and collaborators

Lead sponsor

Colorado State University

Other

Collaborators

  • Florida State University
  • King's College London
  • National Center for Complementary and Integrative Health (NCCIH)
  • University of Utah

Registry information

Acronym: BlueBIOME

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
May 26, 2026
Registry last updated
May 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.